Walleye Trading’s Akebia Therapeutics AKBA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-18,400
Closed -$52K 4742
2020
Q4
$52K Hold
18,400
﹤0.01% 4170
2020
Q3
$46K Sell
18,400
-10,900
-37% -$95.7K ﹤0.01% 3659
2020
Q2
$398K Sell
29,300
-4,100
-12% -$42.4K ﹤0.01% 2463
2020
Q1
$253K Buy
+33,400
New +$260K ﹤0.01% 2426
2019
Q3
Sell
-2,400
Closed -$12K 3966
2019
Q2
$12K Buy
+2,400
New +$13.7K ﹤0.01% 3809

Other funds holding AKBA

Walleye Trading's AKBA Position: Q4 2021 in Review

Walleye Trading sold out of Akebia Therapeutics (AKBA) in Q4 2021, closing a stake of 44,901 shares — an estimated $129K sold.

Walleye Trading first reported a position in AKBA in Q3 2015 and held it in 7 quarters. The position peaked at $340K in Q2 2021. 133 funds tracked by Wall St. Rank hold AKBA as of Q4 2021.

  • Walleye Trading reported no remaining Akebia Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Walleye Trading sold 44,901 Akebia Therapeutics shares in Q4 2021, an estimated $129K.
  • Walleye Trading first reported a position in Akebia Therapeutics in Q3 2015 and held it in 7 quarters.
  • Walleye Trading's Akebia Therapeutics position peaked at $340K in Q2 2021.
  • 133 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2021.

Based on Walleye Trading's 13F filing for Q4 2021, filed 14 Feb 2022.